2017: GeneXion Oncology Prospective Grant of Exclusive Patent License for Mutant IDH1 Inhibitors Useful for Treating Cancer
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On May 31, 2017, we sent the following comment to the NIH regarding the proposed exclusive license on certain patents for cancer treatment to GeneXion Oncology. May 31,… Continue Reading